Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NvA-011
- Development stage
- Preclinical
- Lead developer
- Nova Anchora
- Modality
- Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Recombinant Proteins and Enzymes, Hydrogel Systems → Drug Delivery Systems
- Administration
- Topical
01
Overview
NvA-011 is a recombinant human type VII pro-collagen protein therapy designed for topical application. It is being developed by Nova Anchora as a corrective protein therapy for dystrophic epidermolysis bullosa (DEB), the most severe form of this rare genetic skin disorder. The drug aims to restore the function of type VII collagen, which is deficient in people with DEB, thereby addressing the underlying cause of the disease. The technology was originally developed at Stanford University and licensed to Nova Anchora. As of 2025, NvA-011 remains in preclinical development and has received orphan drug designation from the US FDA[2][3][5].
- Brand names
- NvA-011NvA011NvA 011
- Other names
- NvA-011NvA011NvA 011
Beyond the preview
Go deeper on NvA-011.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NvA-011.